H.I.G. Capital’s Vernacare Acquires Frontier Medical’s Infection Prevention Business
H.I.G. Capital (“H.I.G.”), a leading global alternative asset manager with over €34 billion of equity capital under management, announced today that one of its portfolio companies, UK -based Vernacare, has carved-out the Infection Prevention business from Frontier Medical Group, including the brands Sharpsafe®, Clinisafe® and eXchange™. Terms of the transaction were not disclosed.
The acquired businesses are industry-leaders in the infection prevention market providing an extensive range of sharps and clinical waste disposal solutions. Sharpsafe® was the world’s first purpose-designed plastic sharps container. With a customer base across the UK and Europe, the business operates from its site in Blackwood, Wales.
James Mitchell, Principal at H.I.G. Capital in London, commented on the transaction, “The Frontier Infection Prevention business is a growing industry leader in the manufacture and supply of products that contain and dispose of infectious material safely – critical systems in protecting the Healthcare workforce and limiting the spread of infection. H.I.G. is looking forward to working with Frontier Medical’s Infection Prevention business which is highly complementary to Vernacare’s existing presence in the clinical Infection Prevention sector. We believe the combination will strengthen Vernacare’s market position and support an ambitious organic growth strategy; we will also continue to pursue similar accretive acquisitions in the sector across the UK and internationally over the coming years.”
James Steele, Chief Executive of Vernacare, added, “Frontier’s Infection Prevention business and Vernacare fit very well together, with a common focus on best practice within Infection Prevention, and together, will be even better placed to help improve Infection Prevention standards within UK and overseas healthcare systems.’’
About H.I.G. Capital
H.I.G. is a leading global private equity and alternative assets investment firm with over €34 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:
1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
2.H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
3.H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €27 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
* Based on total capital commitments managed by H.I.G. Capital and affiliates.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Flexjet Advances European Expansion with Delivery of First Embraer Praetor 60030.11.2020 15:03:00 CET | Press release
Flexjet Ltd., offering travelers access to the world’s most luxurious fleet of private jets, accepted delivery of the first Praetor 600 aircraft in its European-based fleet, marking a significant milestone in the expansion of the company’s global business. Flexjet is the only shared-ownership/fractional provider of the Praetor 600, part of a US$1.4 billion order for Embraer Executive Jets, a division of Embraer S.A. (NYSE: ERJ; BM&FBOVESPA: EMBR3), that was announced in October 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005564/en/ Flexjet Embraer Praetor 600 super midsized aircraft part of the European-based Flexjet fleet. (Photo: Business Wire) European Managing Director Marine Eugène leads the team headquartered at Flexjet House in the Mayfair neighbourhood in the west end of London. In addition, Flexjet has opened facilities including a European Tactical Control Centre in the United Kingdom to coordinate f
Diamond Standard Commodity and Token to List on INX30.11.2020 15:00:00 CET | Press release
INX Limited, the blockchain-based platform for trading digital securities and cryptocurrencies, announces today that it has signed a letter of intent with Diamond Standard to list the world’s first diamond commodity—the Diamond Standard Coin. The Coin is a digital and physical asset: a standardized set of diamonds with a wireless chip enabling it to trade as a token on the INX trading platform. The availability of the Coin on the INX platform is pending regulatory approval for the $25 million initial public commodity offering. This diamond commodity makes a $1.2 trillion hard asset available to institutional investors for the first time. Diamond Standard recently announced its plan to launch an ETF on the NYSE under the ticker DIAM, and an agreement to list futures on the CME Globex via the MGEX. INX is providing an electronic spot market for the Diamond Standard Coin. Investors who acquire a Diamond Standard Token on the INX platform are transacting the physical commodity itself, and
Kymeta™ Announces Commercial Availability of its Next-Generation Antenna, Terminal, and Services Making Mobile Global30.11.2020 15:00:00 CET | Press release
Kymeta (www.kymetacorp.com)—the communications company making mobile global—announced that the Kymeta™ u8 and Kymeta Connect™ are available for government and commercial purchase after November 30, 2020, unlocking the potential of broadband satellite connectivity and cellular networks to satisfy the overwhelming demand for communications on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005022/en/ Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, first responders, and commercial customers. Kymeta’s products and services have been field deployed for three years and the demand for the Kymeta u8 presales has already exceeded expectations. With the introduction of the Kymeta u8, the company has meaningfully increased antenna throughput and significantly reduced the total cost of ownership. Kymeta’s new products and services offer a bre
Inversago Pharma Continues to Rapidly Expand Its Leadership Team and Appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer30.11.2020 14:00:00 CET | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as its pipeline of other peripherally-acting CB1 inverse agonists in several other indications. “The appointment of a Chief Medical Officer is an essential element of our corporate strategy as we have entered the clinical phase with our lead compound”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “Glenn brings a broad range of relevant experiences in all aspects of drug development and regulatory interactions and I trust he will have a strong impact on the science we develop at Inversago, helping us meet our objective: developing safe and potent inverse agonists of peripheral CB1 receptors”, added Dr. Ravenelle. “I am very excited to join Inversago a
Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory30.11.2020 13:00:00 CET | Press release
Kinaset Therapeutics, Inc. (“Kinaset” or the “Company”), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Company also announced an exclusive global in-license and services agreement with Vectura Group plc (LSE: VEC) (“Vectura”) to develop and commercialize KN-002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in healthy volunteers and patients is poised to begin in the first half of 2021. Kinaset is led by an experienced management team and Board of Directors with strong backgrounds in the development of respiratory therapeutics. The company is led by Chief Executive Officer Robert Clarke (formerly Pulmatrix, AIR/Alkermes), Chief Business Officer Roger Heerman (GlaxoSmithKline, Vectura), and Chief Development Officer Frazer Morgan (Vec
Collabio Spaces by XCDS at Web Summit 2020: Discover the Benefits of Team Collaboration30.11.2020 11:00:00 CET | Press release
Shaping the future of teamwork is a difficult challenge and Collabio® Spaces by XCDS is ready to take it head on. After several years of stealth mode development, the team which includes former QuickOffice™ engineers released their alternative view on collaboration around documents and co-authoring. Their software works with the majority of popular office document formats and enables real time collaboration even without Internet connection and clouds. Collabio Spaces allows you to share access to your documents whilst keeping them exceptionally and solely on your private mobile or desktop device. The next step in the app's evolution is taking part in Web Summit — the "best technology conference on the planet", according to Forbes. Collabio Spaces team will join 100.000+ attendees, 800+ speakers and 2500+ startups on December 2-4, 2020. The team will speak about technologies behind cloudless collaboration and real time co-authoring, present our product and meet with partners. "We'll joi